GlassScriptPhysician profile
Jeffrey S Stevens
NPI 1962519330
$55,946.36
in general payments reported to CMS, 2019-2025
34 companies · $6,561 in 2025
The $6,561 reported for 2025 was more than what 97% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,663 · 2020: $12K · 2021: $11K · 2022: $10K · 2023: $2,714 · 2024: $4,395 · 2025: $6,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $11K · Consulting Fee: $1,750 · Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $10,711.00 |
| Consulting Fee | $1,750.00 |
| Food and Beverage | $1,209.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Extremity Medical | $53,534.58 | 2019-2025 | Omni Arch, Omni Mini |
| Organogenesis INC. | $401.47 | 2020-2025 | Puraply, Cygnus Dual, Via Matrix |
| Kerecis Limited | $278.90 | 2019-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Stryker Corporation | $274.73 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $208.47 | 2020-2025 | Nuzyra |
| Horizon Therapeutics Plc | $155.24 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $120.94 | 2020-2025 | Collagenase Santyl |
| Depuy Synthes Sales INC. | $117.01 | 2023-2025 | Motoband, Dynaforce |
| Amgen INC. | $110.54 | 2024-2025 | Krystexxa |
| Integra Lifesciences Corporation | $80.51 | 2019-2022 | |
| Medline Industries LP | $80.50 | 2020 | |
| Mimedx Group, INC. | $70.39 | 2025 | |
| Dynasplint Systems INC. | $53.93 | 2021-2025 | Dynasplint |
| Kowa Pharmaceuticals America, INC. | $50.85 | 2023 | Seglentis |
| Convatec INC. | $43.55 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $40.32 | 2021-2022 | |
| Medtronic, INC. | $40.11 | 2023-2025 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $38.77 | 2019 | |
| Tactile Systems Technology INC | $28.80 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Treace Medical Concepts, INC. | $25.14 | 2025 | |
| Boston Scientific Corporation | $21.08 | 2024 | |
| Reprise Biomedical, INC. | $20.01 | 2025 | Miro 3d, Miro3d |
| Paragon 28, INC. | $17.50 | 2019 | |
| Inari Medical, INC. | $17.04 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Avita Medical Americas, LLC | $16.82 | 2024 | |
| Orthofix Medical, INC. | $16.66 | 2024 | Physio-Stim |
| Ibsa Pharma INC. | $14.96 | 2024 | Tirosint, Licart |
| Anika Therapeutics, INC. | $12.87 | 2021 | |
| Kci USA, INC. | $12.43 | 2019 | |
| Zimmer Biomet Holdings, INC. | $12.25 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $10.89 | 2019 | |
| Medela LLC | $10.78 | 2019 | |
| Heron Therapeutics, INC. | $4.81 | 2021 | |
| Grt US Holding, INC. | $3.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.